Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue Friedman

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
JAMA Oncology|October 2, 2015
Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT StudyJoanne Armstrong, Michele Toscano, Nancy Kotchko, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 26, 2016
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the EvidenceMark E Sherman, Ronny I Drapkin, Neil S Horowitz, et al.
Journal of Genetic Counseling|September 12, 2014
American BRCA Outcomes and Utilization of Testing (ABOUT) study: a pragmatic research model that incorporates personalized medicine/patient-centered outcomes in a real world settingJoanne Armstrong, Michele Toscano, Nancy Kotchko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology GuidelineIsabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerPatricia A Ganz, Hanna Bandos, Tanja Španić, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
JAMA Oncology|October 2, 2015
Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT StudyJoanne Armstrong, Michele Toscano, Nancy Kotchko, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 26, 2016
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the EvidenceMark E Sherman, Ronny I Drapkin, Neil S Horowitz, et al.
Journal of Genetic Counseling|September 12, 2014
American BRCA Outcomes and Utilization of Testing (ABOUT) study: a pragmatic research model that incorporates personalized medicine/patient-centered outcomes in a real world settingJoanne Armstrong, Michele Toscano, Nancy Kotchko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology GuidelineIsabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerPatricia A Ganz, Hanna Bandos, Tanja Španić, et al.
Pageof 3